Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - University

University

Luc Willems, FNRS Research Director

ULiège - FNRS - Royal Academy of Medicine of Belgium
" Massive infiltration of activated macrophages is associated with the development of a cytokine storm that leads to severe acute respiratory syndrome induced by SARS-CoV-2. Based on our results demonstrating the key role exerted by epigenetic regulation in the activity of macrophages, we propose to study the methyltransferase EZH2 in the pathogenesis induced by SARS-CoV-2. We have also shown that the PD-1 immune checkpoint is responsible for the macrophage anergy induced by the absence of EZH2. The goal of the project is to temper the excessive inflammatory responses associated with macrophages by interfering on the EZH2-PD-1 axis. "
Funding: Decision pending (FNRS Crédit Urgent de Recherche 40002642)
Publication References: - Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. Malik Hamaidia, Hélène Gazon, Clotilde Hoyos, Gabriela...

Marianne Rooman, FNRS Research Director - Fabrizio Pucci, FNRS Postdoctoral Researcher

ULB - FNRS
" Computational analysis of the impact of SARS-CoV-2 on the renin-angiotensin system. "
Funding: FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

Martinelle Ludovic, Doctor

ULiège
" Collective production of 3D printed face shields and mask clips to be distributed to health care professionals. About 400 face shields were produced and distributed within a month. Collaboration involving CARE-FEPEX and FVM skill lab. "
Contact: Ludovic Martinelle This email address is being protected from spambots. You need JavaScript enabled to view it. 04 366 40 39

Maya Hites, Associate Professor

CUB-Erasme
" "Background: There are no currently approved therapeutics for COVID-19 disease. This disease causes significant morbidity and mortality. Main Objectives: The overall objective of the study is to evaluate the clinical efficacy and safety of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19 patients. The primary endpoint is subject clinical status (on a 7-point ordinal scale) on Day 15. The secondary objectives are to evaluate clinical, and virological efficacy, and safety of different investigational therapeutics as compared to the control arm. Study design: This is a prospective, worldwide, adaptive, randomized, controlled, open study comparing 4 different treatments for COVID-19. The protocol is based on the WHO Master protocol of the Solidarity trial. The DisCoVeRy protocol previews more data collection and lower dosage regimens of Hydroxychloroquine than in the SOLIDARITY trial. Randomization is performed by...

Maya Hites, Associate Professor

CUB-Erasme
" "a. Background Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a new coronavirus SARS CoV-2, responsible for the current pandemic, causing a lot of morbidity and mortality. Most people with COVID-19 develop mild respiratory illness (stage I). However, in a sub-group of patients (+/- 15%) there are increasing respiratory symptoms and persistent fever (stage II). Patients may develop acute lung injury (hypoxia, and bilateral opacities on chest computed tomography (CT-scan)), requiring hospitalisation. A further 5% of patients develop stage III disease, requiring admission to the intensive care unit (ICU) due to acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multi-organ failure. As patients progress from stage I to stage III, there are increasing signs of systemic hyper-inflammatory response, reflected by high levels of cytokines, C-reactive protein (CRP), ferritin, and lymphopenia. Different viral, bacterial, and...

Michel FREDERICH, Professor - Allison LEDOUX, Doctor - Mutien GARIGLIANY, Professor

ULiège, CIRM, FARAH
" Several natural products (i.e. lycorine, glycyrrhizine, extracts of Pelargonium, Echinacea, Sambucus,...) have shown activity against coronaviruses. Several plants have been used in Chinese Medicine to treat patients with COVID-19. The objective of this project is to evaluate several natural products against SARS-COV2 in vitro and confirm their potential for further development. "
Funding: Own funding.
Contact: Prof Michel FREDERICH https://www.cirm.uliege.be This email address is being protected from spambots. You need JavaScript enabled to view it.

Mona Momeni, MD, PhD

UCLouvain/Cliniques universitaires Saint-Luc 
" COVID-19 pandemic has an important impact on the health care provided by the anesthesiologists. Different societies of anesthesiology have provided guidelines and recommendations on how to manage patients who have been tested positive for COVID-19 or suspected to be infected. It is therefore important to know whether these guidelines have been implemented or were possible to be implemented. Otherwise patients who are presenting COVID-19 often show pulmonary complications. The airway management and the ventilation management of these patients can be therefore challenging and can possibly influence their outcome. It is thus important to obtain a large database with information about the characteristics of these patients, how these patients have been managed and their in-hospital outcome. Information regarding the correct implementation of guidelines is as well necessary for future guidance of health care providers. "
Funding: None
Contact...

Mostafa Chamekh, Professor (coordinator of the project) - Georges Casimir, Professor - Francis Corazza, Professor- David de Bels, Doctor

ULB - Royal Academy of Medicine of Belgium
" The project aims at understanding why men are more affected than women. Compelling evidences indicate sex-bias in SARS-CoV2 with male representing the majority of severe cases requiring intensive care. Excessive inflammatory symptoms attributed mainly to cytokine storm is the hall-mark of disease progress. We ask whether differences in genetic fitness between male and female patients could contribute to sex-bias and we focus, in particular, on potential role of microRNAs in fine tuning the type and magnitude of the inflammatory response "
Funding: Current application to FNRS IRIS research
Publication References: - Chamekh M, M Deny, M Romano, et al. Differential Susceptibility to Infectious Respiratory Diseases between Males and Females Linked to Sex-Specific Innate Immune Inflammatory Response. Front Immunol. 2017; 8: 1806. - Casimir, G. J., Lefèvre, N., Corazza, F et al. J. Sex and inflammation in respiratory diseases : a clinical...

Mutien Garigliany, Professor - Daniel Desmecht, Professor

ULiège 
" There is a critical need for therapeutic solutions against SARS-CoV-2. Before implementing innovative treatments in human medicine, a first screening of the antiviral or immunomodulatory activity should be performed by in vitro and in vivo methods. To this aim, we developed in vitro (cell culture) and in vivo (hamsters and mice) models of SARS-CoV-2 infection. We developed an in vitro (cell culture) and in vivo (hamsters and mice) to screen antiviral or immunomodulatory molecules, in partnership with colleagues from the ULiège hospital and the GIGA research center. We also validate the inactivation protocols to facilitate the diagnostic workflow, in partnership with the Federal task force. "
Funding: Currently no funding. We applied to the "Crédits urgents de recherche" call.
Contact: Mutien Garigliany, DVM, PhD, Dipl. ECVP Professor Department of Pathology Faculty of Veterinary Medicine Centre for Fundamental and Applied Research for Animals & Health (FARAH) Liège...

Mutien Garigliany, Professor - Daniel Desmecht, Professor

FARAH - ULiège 
" As of today, one of the most promising therapeutic solutions against COVID-19 is the use of convalescent plasma. A subset of the antibodies present in this plasma are able to bind the surface proteins of the virus, chiefly the Spike (attachment) protein, and to neutralize the ability of viral particles to infect permissive cells. Upon request of the Red Cross and ULiège CHU hospital, we developed seroneutralization assays to determine the titers in neutralizing antibodies of convalescent plasma. In collaboration with KU Leuven (Rega) and ITM Antwerp, we just completed an interlaboratory ring test. We screen convalescent plasmas on a routine basis for the Croix Rouge and Rode Kruis. Only plasmas with a titer in neutralizing antibodies above the cut-off value will be used therapeutically. The scarcity of the scientific literature on the subject (only a few studies on the therapeutic use of convalescent plasmas are currently available) make it difficult to fix a cut-off...

Olivier Debeir, Professor - Olivier Van Hove, Kinesiologist

ULB/ERASME
" Severe COVID-19 patients have a greater risk of long-term health issues and sometimes develop permanent lung damage or fibrosis needing a long treatment to enhance their quality of life. The project aims to better quantify the breathing parameters of a patient to assess his revalidation evolution. A 3D image acquisition based system, provides contacless and non invasive measure. The system can be used as a complementary diagnosis tools as well for a quantitative follow up. "
Funding: So far the project is supported by volunteering inside the ULB/Laboratory of Image Synthesis and Analysis (LISA) and the Erasme Hospital
Contact: Olivier Debeir < This email address is being protected from spambots. You need JavaScript enabled to view it.> & Olivier Van Hove < This email address is being protected from spambots. You need JavaScript enabled to view it.>

Patrice Soumillion, Professor

UCLouvain
" We are designing bacteria that produces the essential protease of COVID-19 and whose activity is associated with sensitivity to a specific antibiotics. This bacteria is a powerful platform for screening potential inhibitors of the protease (the bacteria becomes resistant to the antibiotics if the protease is inhibited). We will use it to screen large combinatorial libraires of cyclic peptides that will be produced by the bacteria as well. "
Funding: Lab funds. FRNS grant application ongoing.
Contact: Patrice Soumillion Louvain Institute of Biomolecular Science and Technology, UCLouvain Place Croix du Sud 4-5 1348 Louvain-la-Neuve

Ph. DELVENNE, FNRS Research Director / Chef de service Anatomie pathologique - J. GUIOT, Chef de clinique Pneumologie - L. RENAUD, Chef de service Pneumologie - M. MOUTSCHEN, Chef de service Infectiologie- B. MISSET, Chef de service Soins Intensifs

ULiège, CHU - Royal Academy of Medicine of Belgium
" Nous faisons face à une pandémie d'infection COVID-19. Ce virus pathogène est source de complications pulmonaires aggravant fortement le pronostic de nos patients. De nos jours, tant les mécanismes physiopathologiques en cause que les marqueurs de sévérité de l'atteinte restent indéterminés. Il apparaît donc comme urgent de pouvoir identifier des marqueurs diagnostiques, pronostiques et prédictifs pour nos patients. Dans ce contexte, plusieurs voies rapidement explorables nous apparaissent comme critiques. Le but final de cette étude est de contribuer à une prise en charge plus ciblée des patients porteurs d'une infection au SRAS-Cov-2. "
Funding: Fonds Léon Frederic
Publication References: Dix publications représentatives : 1) Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting. HUMBLET C, GREIMERS R, DELVENNE P, DEMAN J, BONIVER J, DEFRESNE MP. J Natl Cancer Inst 88 (1996), 824-831. IF...

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Pierre CLOSE, FNRS Research Associate - Francesca RAPINO, Doctor

GIGA-Institute, ULiège - FNRS
" In this project, we study the epitranscriptomic regulation of the SARS-CoV-2. Based on analyses of the viral genome, we investigate the cellular machineries required for the viral replicative cycle. Our goal is to identify possible viral vulnerabilities that can be exploited for the development of innovative anti-viral therapeutic strategies. We investigate possible new therapeutic opportunities based on the analyses of the viral genomic organization and evolution. We speculate that specific cellular machineries are needed to support the viral replicative cycle. Our goal is uncover new antiviral therapeutic strategies based on the viral epitranscriptomic regulation, mRNA translation and protein expression. "
Funding: WELBIO & ULIEGE
Publication References: Rapino F, Delaunay S, Rambow F, Zhou Z, Tharun L, De Tullio P, Sin O, Shostak, Schmitz S, Piepers J, Ghesquière B, Karim L, Charloteaux B, Jamart D, Florin A, Lambert C, Rorive A, Jerusalem G...

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11

info@COVID19-WB.be

Brussels & Wallonia against COVID19